ATE224204T1 - Pharmazeutika und assays die enzymeuntereinheiten anwenden - Google Patents

Pharmazeutika und assays die enzymeuntereinheiten anwenden

Info

Publication number
ATE224204T1
ATE224204T1 AT96903111T AT96903111T ATE224204T1 AT E224204 T1 ATE224204 T1 AT E224204T1 AT 96903111 T AT96903111 T AT 96903111T AT 96903111 T AT96903111 T AT 96903111T AT E224204 T1 ATE224204 T1 AT E224204T1
Authority
AT
Austria
Prior art keywords
agent
pharmaceutics
assay
constituted
components
Prior art date
Application number
AT96903111T
Other languages
English (en)
Inventor
Richard William Titball
Francis Joseph Carr
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovation Ltd filed Critical Biovation Ltd
Application granted granted Critical
Publication of ATE224204T1 publication Critical patent/ATE224204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96903111T 1995-02-22 1996-02-21 Pharmazeutika und assays die enzymeuntereinheiten anwenden ATE224204T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503486.4A GB9503486D0 (en) 1995-02-22 1995-02-22 Pharmaceuticals and assays using enzyme subunits
PCT/GB1996/000380 WO1996025952A1 (en) 1995-02-22 1996-02-21 Pharmaceuticals and assays using enzyme subunits

Publications (1)

Publication Number Publication Date
ATE224204T1 true ATE224204T1 (de) 2002-10-15

Family

ID=10770034

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903111T ATE224204T1 (de) 1995-02-22 1996-02-21 Pharmazeutika und assays die enzymeuntereinheiten anwenden

Country Status (15)

Country Link
US (2) US6472365B1 (de)
EP (1) EP0810880B1 (de)
JP (1) JPH11500136A (de)
KR (1) KR19980702499A (de)
CN (1) CN1188704C (de)
AT (1) ATE224204T1 (de)
AU (1) AU714396B2 (de)
CA (1) CA2213566A1 (de)
DE (1) DE69623755T2 (de)
DK (1) DK0810880T3 (de)
ES (1) ES2182962T3 (de)
GB (1) GB9503486D0 (de)
PT (1) PT810880E (de)
WO (1) WO1996025952A1 (de)
ZA (1) ZA961427B (de)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4463090A (en) * 1981-09-30 1984-07-31 Harris Curtis C Cascade amplification enzyme immunoassay
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
GB8528761D0 (en) 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
US4874710A (en) * 1986-02-20 1989-10-17 Becton Dickinson And Company Assay and product in which binder and liposomes are supported on a solid support
EP0301333A3 (de) * 1987-07-29 1992-07-01 Abbott Laboratories Auf liposomen basierter, homogener Immunoassay für diagnostische Teste
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
JPH04200632A (ja) * 1990-11-29 1992-07-21 Toyo Ink Mfg Co Ltd リポソームの破壊方法
JPH0556797A (ja) 1991-08-31 1993-03-09 Toyo Ink Mfg Co Ltd リポソーム破壊物質の検出方法
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen

Also Published As

Publication number Publication date
DK0810880T3 (da) 2003-01-06
AU4725996A (en) 1996-09-11
EP0810880A1 (de) 1997-12-10
AU714396B2 (en) 2000-01-06
KR19980702499A (ko) 1998-07-15
CN1188704C (zh) 2005-02-09
CA2213566A1 (en) 1996-08-29
JPH11500136A (ja) 1999-01-06
WO1996025952A1 (en) 1996-08-29
PT810880E (pt) 2003-02-28
DE69623755D1 (de) 2002-10-24
ZA961427B (en) 1996-08-07
US6974699B2 (en) 2005-12-13
EP0810880B1 (de) 2002-09-18
GB9503486D0 (en) 1995-04-12
US20020035084A1 (en) 2002-03-21
ES2182962T3 (es) 2003-03-16
DE69623755T2 (de) 2003-06-05
US6472365B1 (en) 2002-10-29
CN1182372A (zh) 1998-05-20

Similar Documents

Publication Publication Date Title
Ciruela et al. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors
Bade et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates
Ekong et al. Recombinant SINAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro
US20080107660A1 (en) Binding Agents
BR9713521A (de)
ES2171676T3 (es) Inmunoensayos por quimioluminiscencia para la deteccion de anticuerpos.
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
DE69407402T2 (de) Repamycinbestimmung
GB2393512A (en) Use of a biochip for the diagnosis of sepsis or sepsis related syndrome
Bialas et al. The ubiquitin-like modifier FAT10 stimulates the activity of deubiquitylating enzyme OTUB1
DK1111385T3 (da) Enzym-protein-kompleks
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
Terlecky et al. Quantitative analysis of peroxisomal protein import in vitro
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
Sugiyama et al. Inositol 1, 4, 5-trisphosphate receptor associated with focal contact cytoskeletal proteins
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
DE60041697D1 (de) Säugetier-rezeptorproteine; ähnliche reagentien und methoden
DE69839130D1 (de) Verwendung einer festphase für einen enzymassay
ATE224204T1 (de) Pharmazeutika und assays die enzymeuntereinheiten anwenden
Bernhard et al. Lateral membrane protein associations of CD4 in lymphoid cells detected by cross-linking and mass spectrometry
ATE110469T1 (de) Nichttrennender festphasen-enzymtest.
Shime et al. Association of Pasteurella multocida toxin with vimentin
Choumet et al. Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
Barrieux et al. Nonidentity of the 48,000-dalton protein of mRNA-protein particles and the beta subunit of eukaryotic initiation factor 2.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0810880

Country of ref document: EP

REN Ceased due to non-payment of the annual fee